Cullen Capital Management LLC Sells 29,045 Shares of Medtronic PLC $MDT

Cullen Capital Management LLC cut its holdings in shares of Medtronic PLC (NYSE:MDT) by 1.1% in the 3rd quarter, Holdings Channel reports. The firm owned 2,672,375 shares of the medical technology company’s stock after selling 29,045 shares during the period. Medtronic makes up approximately 2.8% of Cullen Capital Management LLC’s portfolio, making the stock its 5th largest holding. Cullen Capital Management LLC’s holdings in Medtronic were worth $254,517,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. AXQ Capital LP raised its holdings in shares of Medtronic by 25.6% during the second quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after acquiring an additional 2,013 shares in the last quarter. UMB Bank n.a. raised its holdings in Medtronic by 65.8% in the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after acquiring an additional 54,898 shares during the period. Principal Financial Group Inc. boosted its stake in Medtronic by 17.2% during the 3rd quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock valued at $157,732,000 after purchasing an additional 242,910 shares during the period. Sector Gamma AS increased its position in Medtronic by 35.5% in the 3rd quarter. Sector Gamma AS now owns 303,441 shares of the medical technology company’s stock worth $28,900,000 after buying an additional 79,441 shares during the period. Finally, Verdence Capital Advisors LLC increased its position in Medtronic by 22.0% during the second quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock worth $2,562,000 after acquiring an additional 5,296 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Trading Down 1.3%

Shares of Medtronic stock opened at $101.81 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The business has a fifty day simple moving average of $99.48 and a two-hundred day simple moving average of $95.96. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a market capitalization of $130.52 billion, a price-to-earnings ratio of 27.44, a P/E/G ratio of 2.72 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business’s revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is 76.55%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MDT. The Goldman Sachs Group set a $111.00 target price on Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Citigroup initiated coverage on Medtronic in a report on Tuesday. They issued a “buy” rating and a $117.00 price target for the company. Leerink Partners set a $120.00 price objective on Medtronic and gave the company an “outperform” rating in a research report on Wednesday, November 19th. CICC Research started coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “outperform” rating for the company. Finally, Piper Sandler restated a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $110.67.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic will exercise its option to acquire CathWorks for up to $585 million, adding AI-enabled coronary imaging/diagnostics to its interventional cardiology and cath-lab portfolio — a clear strategic bolt-on that could expand addressable market and recurring software/diagnostic revenues. Medical device maker Medtronic to buy CathWorks in up to $585 million deal Medtronic advances its innovation strategy with intent to acquire CathWorks
• Positive Sentiment: New analyst coverage: Citigroup started coverage with a Buy rating and $117 price target (roughly mid-teens upside from current levels), which can support renewed investor demand and higher price targets among peers.
• Positive Sentiment: Recent quarterly results showed an earnings beat and management set FY26 EPS guidance in the $5.62–$5.66 range, signaling durable margins and cash flow that underpin dividend safety and buyback capacity.
• Positive Sentiment: Dividend/quality narrative remains supportive: coverage highlighting Medtronic as a reliable dividend healthcare pick reinforces interest from income-oriented investors. 2 Healthcare Dividend Stocks That are Just What the Doctor Ordered
• Neutral Sentiment: Company messaging and product launch activity emphasize expansion of heart and diabetes tools, but a recent article notes Medtronic’s valuation is approaching analyst targets — suggesting limited near-term upside unless acceleration in top-line or margin improvement shows up. Medtronic Expands Heart And Diabetes Tools As Valuation Nears Analyst Views
• Negative Sentiment: Leadership change: Nina Goodheart, President of Structural Heart, is retiring — a near-term governance/operational uncertainty for a key growth business that could weigh on sentiment until succession clarity is provided. Medtronic Structural Heart President Nina Goodheart to retire

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).